Skip to content
B

B. Jeevana Jyothi

Publications (4)

Polyethylene Glycol Conjugation for Solubility Enhancement of Cefadroxil, a Poorly Soluble Antibiotic

B. Jeevana Jyothi, Y. Keerthana & N. Deekshita Reddy · Journal of Advances in Medical and Pharmaceutical Sciences · 2022

Introduction: Cefadroxil is the most widely used antibiotic for many bacterial infections but has the drawback of poorly solubility. In an attempt to provide an easier technique which can be scaled up on large scale to provide a simple method to enhance its aqueous solubility, th...

Open access Research Article 10.9734/jamps/2022/v24i530299

Design and Evaluation of Sorafenib Tosylate Nanoparticles Including Assessment of IC50 Values using PC Cell Lines

P. B. Sailaja & B. Jeevana Jyothi · Journal of Pharmaceutical Research International · 2022

Introduction: Sorafenib tosylate is an anticancer drug used for treatment of pancreatic cancer. In the present research work, Sorafenib tosylate is converted to nanoparticles with an aim to assess its anticancer activity with reduced concentration expecting less side effects of t...

Open access Research Article 10.9734/jpri/2022/v34i36B36190

Tenofovir Alafenamide Fumarate Microspheres, Process Parameters for Enhanced Permeability and Liver Targeting

K. Sudhamani & B. Jeevana Jyothi · Journal of Pharmaceutical Research International · 2021

Aims: Chronic hepatitis B (CHB) infection is a serious global health problem and one of the main causes of chronic liver disease, cirrhosis. Tenofovir Alafenamide Fumarate (TAF) is a prodrug of Tenofovir, a nucleotide analogue with limited oral bioavailability. TAF is considered...

Open access Research Article 10.9734/jpri/2021/v33i41A32317

Preparation and Evaluation of Zafirlukast Compression Coated Tablets for Chronotherapeutic Drug Delivery

M. S. Neeharika & B. Jeevana Jyothi · Journal of Pharmaceutical Research International · 2021

The objective of the present study was to formulate and evaluate an oral, time-controlled drug delivery system of Zafirlukast. Zafirlukast belongs to BCS class II drugs as it has poor aqueous solubility and good permeability. Hence an attempt has been made to improve its aqueous...

Open access Research Article 10.9734/jpri/2021/v33i32B31757